RATIONALE: Learning about quality of life, symptoms, and health behaviors in colorectal cancer survivors may help to determine the long-term effects of colon and rectal cancer treatments and may help
Interventions: Experimental group:CAR-T immune cell therapy Primary outcome(s): Successful expansion of CAR-T cells;Objective response rate Study Design: Single arm
BackgroundColorectal cancer (CRC) is the third most common cancer worldwide, with rising incidence linked to unhealthy lifestyle habits. Although 5-fluorouracil (5-FU) remains a standard therapy, its
This study will test the ability of an immune modulator, anti-OX40 (MEDI6469) to alter the immune cell environment within colorectal cancer metastases. The drug will be administered to patients before
